J&J’s Intra‑Cellular buyout, BMS’ oncology gambit, Sanofi’s Blueprint acquisition drive mega deals in H1 2025

Data Compilation
#PharmaFlow

Pipeline Prospector May 2025: Pfizer strikes US$ 6 bn oncology pact; Lilly diversifies pipeline with US$ 2.3 bn in deals

Stock Recap
#PipelineProspector

Sirolimus

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

65 API Suppliers, 30 USDMF, 4 JDMF, 2 EU WC, 4 KDMF, 19 NDC API, 31 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

95 Drugs in Development

95 Drugs in Development

INTERMEDIATES

3 Intermediate Suppliers

3 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

107 FDF Dossiers, 24 FDA Orange Book, 17 Europe, 2 Canada, 16 Australia, 31 South Africa, 17 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 0.5MG, TABLET;ORAL - 1MG, TABLET;ORAL - 2MG, TABLET;ORAL - 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 14 SPI Pharma, 4 DKSH, 4 Faran Shimi Pharmaceutical, 8 Boai NKY Pharmaceuticals Ltd, 4 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 1 ACG Worldwide, 6 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 25 BASF, 11 Corel Pharma Chem, 4 DFE Pharma, 1 Esteem Industries, 2 Finar, 10 Gangwal Chemicals, 4 Ideal Cures, 1 Ingredion Pharma Solutions, 31 Kerry, 4 Kima Chemical, 6 Lonza Capsugel, 14 Microlex e.U, 2 Nanjing Bold Chemical, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 3 Novo Excipients, 3 Pharmatrans-Sanaq, 4 Pluviaendo, 2 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 13 Roquette, 13 Seppic, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 9 Sigachi Industries, 2 Silverline Chemicals, 3 The Dow Chemical Company, 2 Ulanqab Kema New Material, 1 Valens Pharmachem, 2 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

70 Fillers, Diluents & Binders, 46 Coating Systems & Additives, 30 Direct Compression, 29 Controlled & Modified Release, 28 Solubilizers, 25 Thickeners and Stabilizers, 25 Granulation, 22 Disintegrants & Superdisintegrants, 21 Co-Processed Excipients, 16 Taste Masking, 15 Topical, 15 Chewable & Orodispersible Aids, 15 Parenteral, 14 Film Formers & Plasticizers, 12 Lubricants & Glidants, 7 Emulsifying Agents, 5 Rheology Modifiers, 5 Empty Capsules, 5 API Stability Enhancers, 4 Vegetarian Capsules, 4 Coloring Agents, 2 Surfactant & Foaming Agents

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 70 News #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 18 Regulatory FDF Prices, 3 Annual Reports

MARKET PLACE

22 APIs, 4 FDF Dossiers

PATENTS & EXCLUSIVITIES

9 US Patents, 3 US Exclusivities, 17 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 Others

1 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Labeler	NDC Package Code	Non Proprietary Name	Start Marketing Date	End Marketing Date	Category Code	Dosage Form (Strength)
28/06/2025	Chunghwa Chemical Synthesis & Biotech	Taiwan	Chunghwa Chemical Synthesis & Biotech. Ltd	52076-6216	rapamycin	2016-04-29	2025-12-31	BULK INGREDIENT	POWDER (1kg/kg)
28/06/2025	Sumar Biotech	India	Sumar Biotech LLP	85705-001	SIROLIMUS	2025-06-05	2026-12-31	BULK INGREDIENT	POWDER (1g/g)

Sirolimus

Sirolimus

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

65 API Suppliers

30 USDMF

4 JDMF

2 EU WC

4 KDMF

19 NDC API

31 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

95 Drugs in Development

INTERMEDIATES

3 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

107 FDF Dossiers

24 FDA Orange Book

17 Europe

2 Canada

16 Australia

31 South Africa

17 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 0.5MG

TABLET;ORAL - 1MG

TABLET;ORAL - 2MG

TABLET;ORAL - 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc

14 SPI Pharma

4 DKSH

4 Faran Shimi Pharmaceutical

8 Boai NKY Pharmaceuticals Ltd

4 Gangwal Healthcare

4 Nanjing Well Pharmaceutical

2 Pfanstiehl

1 ACG Worldwide

6 Actylis

1 Aeon Procare

1 Alcedo Pharmachem

4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

2 Ashland

25 BASF

11 Corel Pharma Chem

4 DFE Pharma

1 Esteem Industries

2 Finar

10 Gangwal Chemicals

4 Ideal Cures

1 Ingredion Pharma Solutions

31 Kerry

4 Kima Chemical

6 Lonza Capsugel

14 Microlex e.U

2 Nanjing Bold Chemical

2 Nitika Pharmaceutical Specialities

2 Nomisma Healthcare

3 Novo Excipients

3 Pharmatrans-Sanaq

4 Pluviaendo

2 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

13 Roquette

13 Seppic

5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

9 Sigachi Industries

2 Silverline Chemicals

3 The Dow Chemical Company

2 Ulanqab Kema New Material

1 Valens Pharmachem

2 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

TABLET;ORAL - 5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons